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Clinical Expression of Neurotoxic Injury
and Diagnostic Use of Electromyography
by Pamela M. Le Quesne*
The clinical features of neurological damage produced by acrylamide, lead, organophosphates,
hexacarbon solvents, and methylmercury are described, and the differences ineffects ofthese compounds
are stressed. The characteristic pattern ofelectrophysiological changes for each group ofsubstances are
described andcorrelated with pathological rmdings.
Each group ofneurotoxic substances has its own
particulareffect on the nervous system, producing a
typical clinical disorder, pathological changes
which are often distinctive in type and distribution
and resulting in a characteristic pattern of elec-
trophysiological abnormalities. This paper
discusses examples of substances producing
peripheral neuropathy which illustrate these points.
There are often sound reasons for deciding which
particular electrophysiological technique would be
most appropriate for screening exposed populations
to determine whether subclinical orminimal clinical
nerve damage has occurred.
Acrylamide
Acrylamide has been known to be neurotoxic
since the early 1950's, but the clinical features of
acrylamide toxicity to man have been well recog-
nized only for the past 10 years (1). Although the
substance is now extensively used in industry, less
than 50 human cases have been described in the
literature (2). Nevertheless the increasing pollution
of the environment by this substance makes it es-
sential that toxic effects are widely appreciated. A
formidable body ofexperimental work is in progress
to elucidate the underlying mechanism of the
neuropathy.
In elucidating the cause ofperipheral neuropathy,
recognition ofsymptoms and signs other than those
directly related to the peripheral nerves may be
* Medical Research Council Toxicology Unit, Carshalton,
Surrey and Department ofNeurological Studies, The Middlesex
Hospital, London, England.
diagnostically important. In acrylamide poisoning,
the hands usually become red, and the palms peel
and excessive sweating occurs. Weight loss can
occur early. Acrylamide never produces toxic
symptoms after a single exposure however massive,
but high level exposure for a short time causes clini-
cal evidence of CNS involvement, often before the
development ofperipheral neuropathy. Drowsiness
is common; in a family, described by Igisu and col-
leagues (3), whose well water became severely
contaminated with acrylamide, frank en-
cephalopathy developed. Affected subjects de-
veloped drowsiness, memory disturbances, confu-
sion, ataxia and hallucinations at least two weeks
before any evidence ofperipheral neuropathy. With
lesser exposure evidence of peripheral neuropathy
alone may develop slowly. The nerve lesion in-
volves motor and sensory fibers. Cramps occur
early. Distal numbness and paraesthesiae follow,
with distal weakness developing about the same
time or a little later. As the condition progresses
motor involvement is more marked than sensory
loss. All reflexes are lost early, an uncommon find-
ing in toxic neuropathies. When exposure ceases
recovery is complete in mild cases, but slow Im-
provement for a year or more, with slight residual
abnormalities is to be expected in those severely
affected.
Conduction velocity studies in acrylamide
poisoning in rats (4), baboons (5), and man (6) have
consistently shown some fall in maximal nerve con-
duction velocity. When muscle action potentials are
recorded from the small foot muscles following
stimulation of the motor nerves at the ankle and in
the thigh, as described in acrylamide poisoned rats
October 1978 89by Fullerton and Barnes (4), conduction velocity in
the most rapidly conducting nerve fibers in the leg
can be calculated. Figure 1 shows that a reduction
of about 20% occurred in a group of poisoned rats
compared with controls and that velocity recovered
after clinical recovery.
Consideration of pathological changes in the
nerves is important in interpreting these findings.
Acrylamide causes a dying-back type ofneuropathy
in which nerve fiber degeneration begins at the dis-
tal ends of the fibers and spreads proximally as il-
lustrated in Figure 2. Increasingly severe involve-
ment of nerve fibers can be seen as sections are
examined more distally. Figure 3 shows the fiber
diameter distribution in nerves of two control rats,
three acrylamide-poisoned rats, and one during
recovery from acrylamide poisoning. Large diame-
terfibers are predominantly affected. The increased
number of small diameter fibers in the recovering
animal is probably due to the presence of re-
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generating fibers, which are all initially of small
diameter. Conduction velocity is correlated with
fiber diameter and so loss of large diameter fibers
will cause a reduction in maximal conduction ve-
locity while smaller, more slowly conducting fibers
continue to conduct normally. In acrylamide
poisoning there is no evidence of a conduction ab-
normality in fibers which have not degenerated
completely.
Lead
The situation in experimental lead poisoning is
quite different. Experimental poisoning is used as
a
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FIGURE 1. Maximal nerve conduction velocity in motor fibers to
small foot muscles in (a) healthy adult rats, (b) rats which had
been on a diet containing 200 ppm acrylamide for six months
or400 ppm acrylamide fortwo to three months, (c) rats which
had been severely affected and returned to a normal diet five
to nine months previously. Solid lines indicate mean conduc-
tion velocities; dotted lines are two standard deviations from
the mean. From Fullerton (4).
FIGURE 2. Transverse sections of nerves fixed in Flemming's
solution and stained by the modified Weigert method from a
rat which had received a diet containing 200 ppm acrylamide
for six months: (a) lumbar vental root, (b) lumbardorsal root,
(c) sciatic nerve in thigh, (d) posterior tibial nerve above
ankle, (e) sural nerve in mid calf. Calibration: 100,um. From
Fullerton (4).
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FIGURE 3. Histograms showing distribution of myelinated fiber
diameters in posterior tibial nerves of rats on the following
diets: (a), (b) healthy adult rats (c) 400 ppm acrylamide for 2
months, (d) 300 ppm acrylamide for 4 months, (e) 200 ppm
acrylamide for 6 months, (f) 300 ppm acrylamide for4 months
followed by normal diet for 6 months. From Fullerton (4).
an example because frank lead neuropathy in man is
rare today and severe neuropathy in man has not
been studied using modern techniques. In lead-
poisoned guinea pigs, severe reduction in conduc-
tion velocity may occur (7) (Fig. 4). It should be
asked whether such velocities could be associated
with normal conduction in surviving small fibers.
Consideration of Figure 5 makes this unlikely. Fig-
ure 5 shows action potentials recorded from the foot
muscles of a control and lead-poisoned guinea pig
(GPC 27) following stimulation at the ankle (S1) and
in the thigh (S2). The action potential in the
poisoned animal starts after the direct muscle re-
sponse is over in the control animal. The late po-
tential in the control animal is ofreflex origin. Thus,
no normal fibers conduct at the velocity offibers in
the poisoned animal, indicating that pathological
slowing of conduction can occur in individual fi-
bers. Pathological examination of single fibers
shows a different process from the axonal degener-
ation that occurs in acrylamide neuropathies.
Myelin degeneration occurs without degeneration
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FIGURE 4. Maximal motor nerve conduction velocity in relation
to age in control guinea-pigs and guinea-pigs which had re-
ceived repeated doses of 50o lead acetate orally for up to 2
years. From Fullerton (7).
of the axons, producing segmental demyelination.
Although conduction can still occur in many ab-
normal-fibers, it does so at a reduced rate through
the abnormal regions. There is no firm evidence that
segmental demyelination occurs in lead poisoning in
man and marked slowing of conduction, such as
occurs in rats, has never been described in man.
This may be because suitable subjects have not
been investigated or because the pathological pro-
cess is different. Species differencies in the effects
of other toxic agents on the nervous system are
known.
Organophosphates
Some organophosphates produce peripheral
neuropathy and comparison of the clinical, elec-
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FIGURE 5. Muscle action potentials recorded from plantar mus-
cles ofguinea-pigs following supramaximal nerve stimulation
at ankle (SI) and in thigh (S2). GPC27 had received repeated
oral doses of50o lead acetate. Calibration: 1 mV forcontrol,
500 ,uV for GPC27. From Fullerton (7).
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91trophysiological, and pathological features with
those produced by acrylamide illustrate how each
toxic substance produces its own characteristic
findings. Practically all organophosphorus com-
pounds inhibit cholinesterase and acute toxic ef-
fects depend on this action. Sweating, salivation,
vomiting, weakness, fasciculation, and meiosis
occur. The latter two signs are of particular diag-
nostic importance. Most deaths that have occurred
from organophosphate exposure have been the re-
sult ofthis effect. In treatment, atropine will control
cholinergic effects, and pralidoxime has a more di-
rectly curative effect in reversing cholinesterase in-
hibition.
Peripheral neuropathy, which occurs after expo-
sure to some OP compounds, is quite distinct from
the acute effect, and the work of Johnson (8)
suggests that it depends on inhibition of another
specific esterase. Most of the organophosphorus
compounds used as insecticides do not inhibit
''neurotoxic" esterase, do not cause ataxia in hens,
and are most unlikely to produce peripheral
neuropathy in man. Our knowledge of the clinical
features of organophosphorus neuropathy has
largely resulted from cases oftri-o-cresyl phosphate
(TOCP) poisoning (9).
Peripheral neuropathy can, and usually does,
occur after a single exposure, but there is a charac-
teristic latent interval of 10 days to 3 weeks before
neurological symptoms develop. These then pro-
gress rapidly. The clinical features differ in many
ways from those of acrylamide neuropathy. Sen-
sory symptoms and signs are often minimal or ab-
sent even in severe cases. Weakness is even more
restricted to the distal muscles than in acrylamide
neuropathy. There may be no power at all in the
small hand muscles when power in muscles above
the wrist is normally or minimally reduced (personal
observation). Widespread loss of reflexes, particu-
larly at an early stage, does not occur, and ankle
jerks alone may be absent. Pyramidal tracts are fre-
quently affected, again unlike the effects of ac-
rylamide. Clinical evidence of spinal cord involve-
ment may be masked by peripheral neuropathy ini-
tially, but as the peripheral nerves recover, spastic-
ity may become more evident. Since central ner-
vous tissue recovers much less well than peripheral
nerve, more permanent disability can follow OP
neuropathy than follows exposure to toxic sub-
stances whose effects are limited to the peripheral
nerves.
In contrast to acrylamide neuropathy in which a
small reduction in maximal motor nerve conduction
velocity is characteristic, experimental studies in
baboons have shown that in TOCP neuropathy no
reduction in maximal velocity occurs even when
weakness is severe (10). This is illustrated in Figure
6, in which the conduction velocity findings in ba-
boons with TOCP neuropathy studied by Hem (10)
are contrasted with those ofHopkins and Gilliatt (5)
in acrylamide neuropathy. Similarly, in acute or-
ganophosphorus neuropathy in man, normal motor
nerve conduction velocity has been found in the
median nerve supplying grossly weak and wasted
thenarmuscles (Flowler, personal communication).
Organophosphorus neuropathy is a dying-back
disorder superficially similar to acrylamide neu-
ropathy. However, when fiber diameter histograms
of affected nerves were examined in baboons, it
could be seen that there was an overall reduction in
fibernumber, but the fibers oflargest diameter were
not selectively affected (11). Thus one would expect
maximum conduction velocity to be unaffected,
since this value depends on conduction in the
largest surviving fibers. From this it can be pre-
dicted that estimation of motor nerve conduction
velocity would be an inappropriate screening test
for subclinically or minimally affected subjects.
Conversely, in a patient with severe weakness and
wasting due to peripheral neuropathy, normal ve-
locity findings are unusual and might at least raise
the possibility of OP toxicity as a cause. Although
clinically OP neuropathy predominantly affects
motor nerves in man, pathological and electro-
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FIGURE 6. Maximal motor nerve conduction velocity in leg and
amplitude of muscle response recorded from extensor dig-
itorum brevis in baboons with TOCP and acrylamide
neuropathy. Results are expressed as percentages of prein-
toxication values. Results for TOCP compiled from data of
Hem (10) and for acrylamide from data of Hopkins and Gil-
liatt (5).
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involved. Sensory potentials may be abnormal,
when sensation is clinically normal (Fowler, per-
sonal communication). Since, for technical reasons,
measurement ofthe amplitude of sensory nerve ac-
tion potentials as a more sensitive indicator of ab-
normality than the amplitude of muscle action po-
tentials, one is in the paradoxical situation of
suggesting that, to screen for organophosphorus
neurotoxicity, sensory and not motor fibers should
be studied, even though the clinical disorder is pre-
dominantly motor. To decide on the appropriate
electrophysiological investigation would not be
possible without a thorough understanding of the
pathological basis of the disorder and the results of
experimental studies.
Hexacarbons
Another type of peripheral neuropathy of toxic
origin has recently been defined with its own
characteristic clinical, pathological, and elec-
trophysiological features. This neuropathy is
caused by certain hexacarbon solvents and the most
important neurotoxic ones that have been identified
are n-hexane and methyl butyl ketone. Many
cases of peripheral neuropathy have been reported
from Japan resulting from exposure to glues in
which n-hexane was the solvent (12). Peripheral
neuropathy has been a recognized hazard in the
Italian shoe industry for many years, but it is only
recently that n-hexane, again in the glue, has been
identified as the causative agent (13). The most se-
verely affected individuals that have been described
with this disorder have been glue-sniffing addicts
(14). Methyl butyl ketone was responsible for many
cases of peripheral neuropathy in a coated fabrics
plant (15).
During development of neuropathy following ex-
posure to hexacarbons, sensory symptoms usually
occur first, but are mild. Weakness then develops
and progresses more rapidly than sensory loss. In
any but the mildest cases, the condition appears to
be a predominantly motor neuropathy. Even when
severe, weakness remains distal. Ankle jerks are
lost, but other reflexes are usually preserved. When
sensory signs do occur, superficial modalities of
light touch, fast pain and temperature are affected
much more than position sense and deep pain.
In many clinical descriptions of this condition it
has been stressed that deterioration may continue
for weeks, or in one instance up to 3 months (14)
afterexposure ceased. It is important to be aware of
this, because otherwise the diagnosis may be ques-
tioned during the period of deterioration following
cessation ofexposure. During the subsequent year,
or longer, substantial recovery may be expected.
Maximal motor nerve conduction velocity has
been estimated in many of the reported patients
with hexacarbon neuropathy (14, 15). It has often
been found to be substantially reduced, and values
considerably lower than those found in patients
with acrylamide poisoning have been reported. In
the motor nerves in the lower limbs some patients
have been described in whom maximal velocity was
between 25 and 30 m/sec (14, 15). The lower limit
for the control range for maximal velocity in the
lower limbs is approximately 38 m/sec. There is no
evidence to suggest that the slowest conducting
motor fibers in healthy subjects conduct at a veloc-
ity as low as 25 m/sec. Values of this order are
usually seen only when segmental demyelination is
present.
Pathological changes have been described in ex-
perimental hexacarbon neuropathy in animals (16,
17) and following nerve biopsy in man (14). The
changes have been similar. Giant axonal swellings
filled with neurofilaments develop at intervals along
the nerve fibers. Secondary myelin changes occur
at the site of the swelling. These often occur in the
paranodal region and are associated with myelin
retraction from the node. Myelin thinning may be
seen over other swellings. Thus, although this
seems to be the first instance of a primary axonal
neuropathy associated with substantial reduction in
conduction velocity, this can probably be related to
secondary structural changes in the myelin sheath,
since the properties of the myelin sheath are of
prime importance in determining conduction veloc-
ity.
In a condition such as this, in which marked
slowing of conduction occurs in clinically severely
affected patients, measurement of maximal motor
nerve conduction velocity would be an appropriate
electrophysiological investigation to apply to
groups of exposed individuals. In subclinically af-
fected individuals, velocity would probably fall
within the control range but it is likely that differ-
ences would become apparent if a subclinically af-
fected group was compared with a control group of
subjects.
Methylmercury
One of the earliest effects of methylmercury in
rats is damage to dorsal rootgangliancells, resulting
in degeneration of sensory fibers in peripheral
nerves (18). The earliest symptoms in man consist
October 1978 93of paraesthesiae in the fingers and toes and fre-
quently around the mouth and on the tongue. From
this one might predict that electrophysiological
studies on peripheral nerve sensory fibers would
give an objective measure ofthe severity ofthe dis-
order. The amplitude of sensory nerve action po-
tentials can be measured accurately. With loss of
fibers or slowing of conduction in individual fibers
producing dispersion ofthe potential, amplitude will
fall.
However in this instance there is a marked differ-
ence in the effect ofthe compound, methylmercury,
on different species.
As already described, methylmercury in man ini-
tially causes paraesthesiae. These are followed by
ataxia and visual disturbances (19). Only in very
severely affected subjects are there more wide-
spread effects on the nervous system. Abnormal
movements, myoclonus, disturbances of con-
sciousness and motor involvement occur at an ad-
vanced stage ofpoisoning. Ataxia is due to affection
ofthe granular cells in the cerebellum (20). Gait and
truncal movements are affected to a greater extent
than individual limbs. The visual disturbance is due
to involvement of cells in the occipital cortex,
and characteristically there is concentric constric-
tion ofthe visual fields with preservation ofnormal
acuity in a small central field ofvision (19, 20). This
combination of symptoms does not occur in any
other disease or condition and these clinical fea-
tures are, thus, diagnostic of methylmercury
poisoning.
Methylmercury poisoning in man has occurred in
two distinct situations. One has occurred as a result
of inorganic mercury in industrial waste being dis-
charged into the sea or rivers. Small aquatic or-
ganisms convert the mercury to an organic form
which becomes concentrated in larger fish which
are then eaten by man. This occurred in Minamata
and Niigata in Japan, and much ofour knowledge of
organic mercury poisoning has come from the study
of patients affected in these episodes (21). Other
large outbreaks have occurred as a result ofpeople
accidentally eating grain treated with methylmer-
cury as afungicide. This occurred in a large episode
in Iraq in 1971 (22). Instead of sowing the grain,
which would have produced a nontoxic crop, the
grain was eaten. At least 6500 people were affected,
with 459 recorded deaths.
Electrophysiological studies were carried out on
19 of the Iraqi subjects, all of whom had clinical
evidence of moderate or severe organic mercury
poisoning (23). All had had some sensory distur-
bance, most had had paraesthesiae, and 13 still had
abnormal sensory signs in the limbs when the tests
were carried out four months after the onset of
symptoms. No abnormality of conduction velocity
or of sensory nerve action potential amplitude was
found in any ofthe patients and no differences could
be detected between the results for the whole group
and a group of age matched control subjects. Ifthe
sensory symptoms and signs had been due to in-
volvement of peripheral nerve fibers, then abnor-
malities would have been present. With this poison
one can say that electrophysiological tests have
shown that peripheral nerves are not affected in
man, and that sensory symptoms must be due to
abnormalities of the central nervous system; the
effect ofthe poison in man is in some ways different
from that in the rat.
I am grateful to the editor of British Journal of Industrial
Medicine for permission to publish Figs. 1, 2 and 3 and to the
editor ofJournal ofNeuropathology and Experimental Neurol-
ogy for Figs. 4 and 5.
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